Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.
Influenza Other Respir Viruses
; 18(2): e13255, 2024 Feb.
Article
in En
| MEDLINE
| ID: mdl-38403302
ABSTRACT
We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI -23-36); 20% (95% CI -4-39) against A(H3N2) and 56% (95% CI 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia
/
Influenza Vaccines
/
Influenza, Human
/
Influenza A Virus, H1N1 Subtype
Limits:
Adult
/
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Influenza Other Respir Viruses
Journal subject:
VIROLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: